GS
XLO icon

Gilead Sciences’s Xilio Therapeutics XLO Stock Holding History

Gilead Sciences’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.47M Hold
650,389
– – 0.26% 6
2025
Q4 		$5.83M Hold
650,389
– – 0.3% 6
2025
Q3 		$7.67M Hold
650,389
– – 0.43% 8
2025
Q2 		$6.19M Hold
650,389
– – 0.48% 8
2025
Q1 		$6.6M Hold
650,389
– – 0.56% 8
2024
Q4 		$8.7M Buy
+650,389
New +$8.95M 0.56% 9

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

Gilead Sciences's XLO Position: Q1 2026 in Review

Gilead Sciences held its Xilio Therapeutics (XLO) position steady in Q1 2026 at 650,389 shares worth $5.47M. The position accounts for 0.26% of the portfolio, ranked #6.

Gilead Sciences first reported a position in XLO in Q4 2024 and has held it in 6 quarters since. The position peaked at $8.7M in Q4 2024. 24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

  • Gilead Sciences held 650,389 shares of Xilio Therapeutics worth $5.47M as of Q1 2026.
  • Gilead Sciences left its Xilio Therapeutics share count unchanged in Q1 2026.
  • Xilio Therapeutics made up 0.26% of Gilead Sciences's portfolio in Q1 2026, its #6 holding.
  • Gilead Sciences first reported a position in Xilio Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Gilead Sciences's Xilio Therapeutics position peaked at $8.7M in Q4 2024.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on Gilead Sciences's 13F filing for Q1 2026, filed 8 May 2026.